Serum anti-SARS-CoV-2 specific antibody titers after infection
infection, RBD, PCR-confirmed SARS-CoV-2 infections
INFECTION, VIRUS
The study participants self-reported 14 PCR-confirmed SARS-CoV-2 infections and one additional infection was confirmed by the emergence of anti-N IgG antibodies (the subject was symptomatic but had tested negative). However, three subjects (two in the probiotic group, one in the placebo group) were vaccinated between their infection and sampling which meant that their anti-S IgG/IgA, anti-RBD IgG/IgA, and virus neutralizing antibody (nAB) results were excluded from these analyses leaving six participants in each study arm for these analyses.The median serum anti-S IgG titer was 609 (168–1,480) BAU/ml in the active treatment arm (Serum anti-SARS-CoV-2 specific antibody (a-f) and virus-neutralizing antibody levels (g) in study participants who were infected during the study period (intention-to-treat population). S = spike, RBD = receptor-binding domain, 